Rheumatism News and Research RSS Feed - Rheumatism News and Research

Rheumatism is a group of disorders marked by inflammation or pain in the connective tissue structures of the body. These structures include bone, cartilage, and fat.
ICS users may be at greater risk for nontuberculous mycobacteria pulmonary disease

ICS users may be at greater risk for nontuberculous mycobacteria pulmonary disease

Patients with obstructive lung disease who take inhaled corticosteroids (ICS) may be at greater risk for nontuberculous mycobacteria pulmonary disease (NTM PD), according to new research presented at the ATS 2016 International Conference. [More]
Better education for patients, doctors on disease symptoms may help reduce leprosy in Brazil

Better education for patients, doctors on disease symptoms may help reduce leprosy in Brazil

Better education for both patients and doctors on how to spot the early symptoms of leprosy would help to reduce cases of the disease in Brazil, according to a study led by researchers at the University of Birmingham. [More]
People diagnosed with psoriatic arthritis often left with little or no support for emotional problems

People diagnosed with psoriatic arthritis often left with little or no support for emotional problems

In a new University of Manchester study, people with psoriatic arthritis have told researchers about the condition's deeply damaging mental effects and how healthcare services failed to prepare them for its reality. [More]
Study supports screening for HLA-B*5801 gene variant in Asian, black patients with gout

Study supports screening for HLA-B*5801 gene variant in Asian, black patients with gout

A multi-institutional study led by a Massachusetts General Hospital investigator finds significant racial disparities in the risk that patients being treated for gout will develop a serious, sometimes life-threatening adverse reaction to the most commonly prescribed medication. The increased risk closely correlates with the frequency of a gene variant previously associated with that adverse reaction, supporting recommendations to screen for that variant in patients from those populations. [More]
Bonn scientists identify immune factor partially responsible for chronic viral infection

Bonn scientists identify immune factor partially responsible for chronic viral infection

Many viral diseases tend to become chronic - including infections with the HI virus. In persons affected, the immune response is not sufficient to eliminate the virus permanently. [More]
Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD). [More]
"Neoehrlichiosis" Internationally Diagnosed And Successfully Treated In Patients Without Immunodeficiency For The First Time

"Neoehrlichiosis" Internationally Diagnosed And Successfully Treated In Patients Without Immunodeficiency For The First Time

The intercellular bacteria "Candidatus Neoehrlichia", as e.g. Borrelia, can be transferred by ticks. Approx. 4.2 % of indigenous ticks are infected with this rarely explored bacterium which, until today, has been exclusively identified as pathogenic bacterium in patients with an impairment of the immune system, such as in case of leukaemia, rheumatism or after organ transplantation. [More]
Influenza virus can able to circumvent the body's immune system

Influenza virus can able to circumvent the body's immune system

Influenza is able to mask itself, so that the virus is not initially detected by our immune system. This is the result of new research from Aarhus University. The researchers behind the study hope that the discovery can be used to develop better treatment against influenza and chronic inflammation conditions such as rheumatoid arthritis. [More]
New way to antagonize human nuclear receptor

New way to antagonize human nuclear receptor

On Monday 7 December the journal Nature Communications published the research findings of Eindhoven University of Technology (TU/e), Merck Research Laboratories (Merck is known as MSD outside the US and Canada) and Leiden University concerning an entirely new way of antagonizing a human nuclear receptor. [More]
Researchers identify molecular switch that can avoid inflammation

Researchers identify molecular switch that can avoid inflammation

Our immune system is vital to us and can sometimes overreact causing chronic illnesses, such as for instance rheumatism and allergy. Now, researchers from Umeå University and University of Gothenburg have identified a molecular switch - MYSM1 - that can suppress such an overreaction and avoid inflammation. [More]
Experts and researchers develop new classification criteria for gout

Experts and researchers develop new classification criteria for gout

A panel of experts and researchers have developed a new classification system for gout, the most common form of inflammatory arthritis. This new system standardizes the classification of this condition using a variety of evidence-based criteria. [More]
ACR releases two new publications to improve treatment of polymyalgia rheumatica, gout

ACR releases two new publications to improve treatment of polymyalgia rheumatica, gout

The American College of Rheumatology (ACR) has released two new publications - recommendations aimed at improving the treatment of patients with polymyalgia rheumatica (PMR), and new classification criteria for gout. [More]
Autoantibody status fails to predict death risk in systemic sclerosis with PAH

Autoantibody status fails to predict death risk in systemic sclerosis with PAH

Anticentromere and isolated nucleolar autoantibodies are prevalent in systemic sclerosis patients with pulmonary arterial hypertension, but they do not predict survival, US research shows. [More]
Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline. [More]
ImmunArray to launch SLE-key Rule Out test for lupus in select U.S. markets

ImmunArray to launch SLE-key Rule Out test for lupus in select U.S. markets

At the premier European forum on rheumatologic disorders, ImmunArray, maker of a breakthrough technology that provides unprecedented levels of accuracy in ruling out the presence of lupus through a simple blood test, announced today that it is launching its new SLE-key™ Rule Out test in selected U.S. markets on July 1, 2015. [More]
Study shows that TNFi dose reduction strategy can help in optimal management of RA

Study shows that TNFi dose reduction strategy can help in optimal management of RA

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis (RA) patients, a good clinical response to maintenance treatment with a tumour necrosis factor inhibitor (TNFi) was maintained even when the dose was reduced by one-third. [More]
People with rheumatoid arthritis less likely to benefit from hepatitis B vaccine

People with rheumatoid arthritis less likely to benefit from hepatitis B vaccine

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that people with rheumatoid arthritis (RA) are less likely to be protected by hepatitis B vaccination than the general population. [More]
Hydroxychloroquine drug fails to reduce mild-moderate pain from primary hand osteoarthritis

Hydroxychloroquine drug fails to reduce mild-moderate pain from primary hand osteoarthritis

The results of an interventional trial presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that use of the disease-modifying anti-rheumatic drug hydroxychloroquine for 24 weeks did not diminish mild-moderate pain from primary hand osteoarthritis (OA). [More]
Study identifies unique bacterial signature in people with systemic sclerosis

Study identifies unique bacterial signature in people with systemic sclerosis

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) Press Conference showed that people with systemic sclerosis (SSc) have a unique bacterial signature in their colon, when compared with healthy people. [More]
NSAIDs significantly inhibit ovulation in women with mild musculoskeletal pain

NSAIDs significantly inhibit ovulation in women with mild musculoskeletal pain

The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) show that diclofenac, naproxen and etoricoxib significantly inhibit ovulation in women with mild musculoskeletal pain. Of the women receiving NSAIDs, only 6.3 percent (diclofenac), 25 percent (naproxen) and 27.3 percent (etoricoxib) ovulated, compared with 100 percent of the control group. [More]
Advertisement
Advertisement